Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Power estimations for non-primary outcomes in randomised clinical trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Helle B Krogh
  • Ole Jakob Storebø
  • Erlend Faltinsen
  • Adnan Todorovac
  • Erica Ydedahl-Jensen
  • Frederik Løgstrup Magnusson
  • Mathilde Holmskov
  • Trine Gerner
  • Christian Gluud
  • Erik Simonsen
Vis graf over relationer

OBJECTIVE: To assess the methodological advantages and disadvantages of parallel and crossover designs in randomised clinical trials on methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

DESIGN: Secondary analyses of a Cochrane systematic review.

SETTING AND PARTICIPANTS: We searched relevant databases up to March 2015 and included data from parallel and crossover randomised trials assessing children and adolescents up to 18 years with ADHD.

INTERVENTIONS: Methylphenidate compared with placebo or no-treatment interventions.

PRIMARY AND SECONDARY OUTCOMES: The primary outcomes were teacher-rated ADHD symptoms and serious adverse events. The secondary outcomes were non-serious adverse events.

RESULTS: We included 38 parallel trials (n=5111) and 147 crossover trials (n=7134). When comparing methylphenidate with placebo or no-treatment on ADHD symptoms, we found no differences between the end of parallel trials and the first-period from crossover trials (Χ²=1.06, df=1, p=0.30, I²=5.5%). We also found no differences when combining the end of first-period crossover trials with the end of parallel trials and comparing them to the end of last-period crossover trials (Χ²=3.25, df=1, p=0.07, I²=69.2%). We found no differences in serious and non-serious adverse events, and no risk of period and carryover effects. However, only two trials contributed data to the latter analyses.

CONCLUSIONS: Both parallel and crossover trials seem suitable for investigating methylphenidate in children and adolescents with ADHD, with comparable estimates on ADHD symptom severity and adverse events. However, parallel trials might still offer ethical and statistical advantages over crossover trials.

OriginalsprogEngelsk
TidsskriftBMJ Open
Vol/bind9
Udgave nummer3
Sider (fra-til)e026478
ISSN2044-6055
DOI
StatusUdgivet - 30 mar. 2019

Bibliografisk note

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 56915250